Related references
Note: Only part of the references are listed.Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators
A. Fassio et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss
Juliane Colditz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Antiresorptive and anabolic agents in the prevention and reversal of bone fragility
Ego Seeman et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Glucocorticoid-induced osteoporosis: 2019 concise clinical review
G. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Pro-inflammatory Cytokines and Osteocytes
Miao Zhou et al.
CURRENT OSTEOPOROSIS REPORTS (2019)
The Role of Osteocytes in Inflammatory Bone Loss
Corinne E. Metzger et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials
Anne-Birgitte Garm Blavnsfeldt et al.
BONE (2018)
Glucocorticoids, Inflammation and Bone
Melek Guler-Yuksel et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis
Yubo Ma et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Glucocorticoid-induced osteoporosis: an update
Juliet Compston
ENDOCRINE (2018)
Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications
Jae-hyuck Shim et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases
Mai Kawazoe et al.
CLINICAL RHEUMATOLOGY (2018)
Biologic therapies and bone loss in rheumatoid arthritis
C. A. F. Zerbini et al.
OSTEOPOROSIS INTERNATIONAL (2017)
New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application
Angelo Fassio et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis
Yi-Ming Chen et al.
PLOS ONE (2017)
In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls
Angelo Fassio et al.
CLINICAL RHEUMATOLOGY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength
W. Yao et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis
Giovanni Adami et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin
Amy Y. Sato et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis
A. Fassio et al.
REUMATISMO (2016)
The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis
Karine Briot et al.
JOINT BONE SPINE (2015)
Tumor Necrosis Factor and Interleukin-6 Differentially Regulate Dkk-1 in the Inflamed Arthritic Joint
Nataliya Yeremenko et al.
ARTHRITIS & RHEUMATOLOGY (2015)
The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis
Kensuke Kume et al.
RHEUMATOLOGY (2014)
The Role of Wnt Signaling and Sclerostin in the Pathogenesis of Glucocorticoid-Induced Osteoporosis
Nuria Guanabens et al.
CURRENT OSTEOPOROSIS REPORTS (2014)
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
Xiao-Xiang Chen et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover
L. Gifre et al.
BONE (2013)
Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes
Kristyna Brabnikova Maresova et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
Gisela Ruiz Heiland et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
Georg Schett et al.
NATURE REVIEWS RHEUMATOLOGY (2012)
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2009)
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin
Alexander G. Robling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
G. Saviola et al.
RHEUMATOLOGY (2007)
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra et al.
NATURE MEDICINE (2007)
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate -: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes
Robert Landewe et al.
ARTHRITIS AND RHEUMATISM (2006)
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength
CA O'Brien et al.
ENDOCRINOLOGY (2004)
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
P Garnero et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
